IRIS
SERVETTO, ALBERTO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 579
EU - Europa 505
AS - Asia 207
AF - Africa 27
Totale 1.318
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 573
IT - Italia 384
SG - Singapore 113
CN - Cina 48
NL - Olanda 36
CI - Costa d'Avorio 27
DE - Germania 27
IN - India 23
FI - Finlandia 14
IE - Irlanda 13
FR - Francia 12
PK - Pakistan 11
CA - Canada 6
BE - Belgio 4
GB - Regno Unito 4
VN - Vietnam 4
IR - Iran 3
RU - Federazione Russa 3
GR - Grecia 2
MY - Malesia 2
SE - Svezia 2
UA - Ucraina 2
AZ - Azerbaigian 1
CZ - Repubblica Ceca 1
ES - Italia 1
JP - Giappone 1
UZ - Uzbekistan 1
Totale 1.318
Salva come PNG Salva come JPEG
Città #
Naples 112
Singapore 95
Chandler 90
Ashburn 69
Napoli 48
Amsterdam 34
Millbury 24
Santa Clara 21
Boston 17
Lawrence 16
Beijing 15
Des Moines 14
Pune 13
Rome 13
Formia 11
Princeton 10
Hicksville 9
Munich 9
Nanjing 8
San Mateo 8
Modica 7
Seattle 7
Turin 7
Wilmington 6
Frankfurt am Main 5
Milan 5
Nanchang 5
Caserta 4
Dong Ket 4
Fucecchio 4
Hebei 4
Helsinki 4
Islamabad 4
Kolkata 4
Lahore 4
Ottawa 4
Pomigliano d'Arco 4
Portici 4
Salerno 4
San Giorgio a Cremano 4
Woodbridge 4
Amalfi 3
Angri 3
Ardabil 3
Brussels 3
Casagiove 3
Castel San Giovanni 3
Fairfield 3
Genoa 3
Moscow 3
Mumbai 3
Pizzo 3
Boardman 2
Chengdu 2
Council Bluffs 2
Duncan 2
Falkenstein 2
Harbin 2
Krefeld 2
Kuala Lumpur 2
Lappeenranta 2
Lomazzo 2
Luco dei Marsi 2
Maiori 2
Palermo 2
Palma Campania 2
Pimonte 2
Pozzuoli 2
Prato 2
Pátrai 2
Rawalpindi 2
Redwood City 2
Uzhhorod 2
Afragola 1
Augusta 1
Baku 1
Bangalore 1
Brno 1
Buffalo 1
Casalnuovo 1
Casoria 1
Changchun 1
Changsha 1
Changzhou 1
Cologne 1
Dongguan 1
Dublin 1
Ercolano 1
Espoo 1
Giugliano In Campania 1
Hanover 1
Houston 1
Indiana 1
Jacksonville 1
Jiaxing 1
Kagoya 1
La Canada Flintridge 1
La Louvière 1
Lanuvio 1
Leawood 1
Totale 836
Salva come PNG Salva come JPEG
Nome #
Urokinase-type plasminogen activator receptor (uPAR) expression enhances invasion and metastasis in RAS mutated tumors 92
Hedgehog signalling pathway orchestrates angiogenesis in triple-negative breast cancers 67
C-Src and EGFR inhibition in molecular cancer therapy: What else can we improve? 63
1599P - Effects of Hedgehog signaling inhibition on epithelial-stromal interactions in triple negative breast cancer cells 57
Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status 53
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer. 48
Mechanisms of resistance to mTOR inhibitors 46
Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells 44
FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules 44
Everolimus induces Met inactivation by disrupting the FKBP12/Met complex 43
Neoadjuvant Treatment in Locally Advanced Pancreatic Cancer (LAPC) Patients with FOLFIRINOX or Gemcitabine NabPaclitaxel: A Single-Center Experience and a Literature Review. 43
Use of folfirinox or nab-paclitaxel plus gemcitabine for the treatment of locally advanced pancreatic adenocarcinoma: A single institution observational study 43
The dual PI3K/mTOR inhibitor PKI-587 enhances sensitivity to cetuximab in EGFR-resistant human head and neck cancer models. 38
P0081 Src inhibitors act through different mechanisms to cooperate with EGFR or MEK inhibitors in NSCLC models sensitive or resistant to erlotinib 38
Real-world clinical outcome and safety of adjuvant therapy in stage III melanoma patients: Data from two Academic Italian Institutions 36
A review of the use of next generation sequencing methodologies to identify biomarkers of resistance to CDK4/6 inhibitors in ER+/HER2- breast cancer 36
Inadequate health-related quality of life assessment and reporting in phase III clinical trials of immune checkpoint inhibitors in solid cancers: a systematic review 36
ER+ breast cancers resistant to prolonged neoadjuvant letrozole exhibit an E2F4 transcriptional program sensitive to CDK4/6 inhibitors 33
Tumour microenvironment and immune evasion in EGFR addicted NSCLC: Hurdles and possibilities 33
FGFR1 Amplification Mediates Endocrine Resistance but Retains TORC Sensitivity in Metastatic Hormone Receptor-Positive (HR+) Breast Cancer. 33
Delayed response to maintenance therapy after first-line chemotherapy in metastatic intrahepatic cholangiocarcinoma: A case report 32
Insight on the Role of Leptin: A Bridge from Obesity to Breast Cancer 31
FGFR signaling and endocrine resistance in breast cancer: Challenges for the clinical development of FGFR inhibitors 31
Pak1 pathway hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer 29
RET rearrangements in non-small cell lung cancer: Evolving treatment landscape and future challenges 29
Hyperactivation of TORC1 Drives Resistance to the Pan-HER Tyrosine Kinase Inhibitor Neratinib in HER2-Mutant Cancers 29
Nuclear FGFR1 regulates gene transcription and promotes antiestrogen resistance in ERþ breast cancer 29
FOLFIRINOX or nab-paclitaxel plus gemcitabine in metastatic pancreatic adenocarcinoma: an observational study 26
Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer 25
FGFR1 associates with gene promoters and regulates gene transcription: Implications for endocrine resistance in ER+/FGFR1-amplified breast cancer 25
Role of FGFR3 in bladder cancer: Treatment landscape and future challenges 24
Health-related quality of life is underestimated and underreported in phase III clinical trials in NSCLC 22
Combined blockade of mTOR and p21-activated kinases pathways prevents tumour growth in KRAS-mutated colorectal cancer 21
Co-occurring gain-of-function mutations in HER2 and HER3 modulate HER2/HER3 activation, oncogenesis, and HER2 inhibitor sensitivity 19
Analysis of Health-Related Quality of Life Reporting in Phase III RCTs of Advanced Genitourinary Tumors 16
Exploring the interplay between Kaposi's sarcoma and SARS‐CoV‐2 infection: A case series and systematic review 14
Correction: ER+ breast cancers resistant to prolonged neoadjuvant letrozole exhibit an E2F4 transcriptional program sensitive to CDK4/6 inhibitors (Clinical Cancer Research (2018) 24 (2517–29) DOI: 10.1158/1078-0432.CCR-17-2904) 14
Epigenetic Repression of STING by MYC Promotes Immune Evasion and Resistance to Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer 14
FGFR1 Antibody Validation and Characterization of FGFR1 Protein Expression in ER+ Breast Cancer 12
Case report: Potential role of immunotherapy in thymic malignancies: a unique case of a durable and complete response upon an immune checkpoint inhibitor 10
COVID-19 in patients with thymic epithelial tumors with or without Good's syndrome: a single-center retrospective study 9
DLL3 as a potential diagnostic and therapeutic target in neuroendocrine neoplasms: A narrative review 9
Moving Immune Checkpoint Inhibitors to Early Non-Small Cell Lung Cancer: A Narrative Review 9
Consolidative thoracic radiation therapy for extensive-stage small cell lung cancer in the era of first-line chemoimmunotherapy: preclinical data and a retrospective study in Southern Italy 5
Systematic review and meta-analysis of immune checkpoint inhibitors as single agent or in combination with chemotherapy in early-stage non-small cell lung cancer: Impact of clinicopathological factors and indirect comparison between treatment strategies 5
EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer 3
Malignant granular cell tumor of chest wall: a case report 3
PRMT5 is an actionable therapeutic target in CDK4/6 inhibitor-resistant ER+/RB-deficient breast cancer 3
Analysis of phase III clinical trials in metastatic NSCLC to assess the correlation between QoL results and survival outcomes 3
Breast-cancer specific comprehensive archive of Patient-Reported Outcome Measures (PROMs) for clinical research and clinical practice in oncology: Results from the PRO4All project 1
Totale 1.428
Salva come PNG Salva come JPEG
Categoria #
all - tutte 7.182
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 7.182
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202046 0 0 0 0 0 8 0 7 1 8 15 7
2020/202195 3 0 2 0 11 6 4 6 19 14 19 11
2021/2022183 5 0 8 10 4 9 4 4 32 17 38 52
2022/2023347 35 11 15 9 45 36 14 31 51 42 34 24
2023/2024352 14 34 61 22 17 54 23 36 9 10 47 25
2024/2025255 51 68 4 79 51 2 0 0 0 0 0 0
Totale 1.428